Dennis Karl Huang - 01 Mar 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP, Chief Technical Operations Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
01 Mar 2026
Net transactions value
-$23,367
Form type
4
Filing time
03 Mar 2026, 18:49:10 UTC
Previous filing
04 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Huang Dennis Karl EVP, Chief Technical Operations Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO /s/ Karah Parschauer, attorney-in-fact 03 Mar 2026 0001641217

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +11,137 +9.7% $0.000000 125,728 01 Mar 2026 Direct F1
transaction RARE Common Stock Tax liability $23,367 -999 -0.79% $23.39 124,729 02 Mar 2026 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metric.
F2 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Remarks:

EVP, Chief Technical Operations Officer